SCHEMBL12640325

SCHEMBL12640325

Clc1ccc(CNc2ccc(Br)cn2)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
KDM4E B2RXH2 3/20 0.56
ALDH1A1 P00352 3/20 0.56
MAPK1 P28482 1/20 0.56
MAPT P10636 5/20 0.55
GAA P10253 4/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
MEN1 O00255 6/20 0.51
KMT2A Q03164 6/20 0.51
PKM P14618 3/20 0.51
HPGD P15428 2/20 0.51
HTT P42858 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51
GFER P55789 1/20 0.50
HIF1A Q16665 1/20 0.50
RAB9A P51151 4/20 0.49
LMNA P02545 1/20 0.47
ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1266734 0.84 NPC1 (0.62) NPC1SMN1; SMN2KDM4EALDH1A1MAPK1
SCHEMBL29996542 0.81 KDM4E (0.55) NPC1SMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL12640351 0.79 MAPT (0.53) NPC1SMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL12675580 0.79 KDM4E (0.53) SMN1; SMN2KDM4EALDH1A1MAPTGAA
SCHEMBL12675385 0.78 CYP3A4 (0.52) SMN1; SMN2KDM4EALDH1A1MAPTGAA
SCHEMBL2599915 0.78 NPC1 (0.56) NPC1SMN1; SMN2KDM4EALDH1A1MAPK1
SCHEMBL2599920 0.78 NPC1 (0.52) NPC1SMN1; SMN2KDM4EALDH1A1MAPK1
SCHEMBL23609081 0.78 ALDH1A1 (0.62) NPC1SMN1; SMN2KDM4EALDH1A1MAPK1
SCHEMBL28892323 0.77 KDM4E (0.53) SMN1; SMN2KDM4EALDH1A1MAPTGAA
SCHEMBL2685939 0.76 CXCR4 (0.69) NPC1SMN1; SMN2KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF NPC1 4477/4885SMN1; SMN2 620/4885KDM4E 2135/4885
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF NPC1 4477/4885SMN1; SMN2 620/4885KDM4E 2135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.